1. 1. World Health Organization. Global status report on non-communicable diseases. Geneva: World Health Organization; 2014. Link
2. Heydarpour F, Akbari Sari A, Mohebali M, Bokaie S. Economic burden of cutaneous and visceral lishmaniasis in Iran in 2013. Iran J Epidemiol 2017;13(1):1-13. Link
3. Javadi M, Asgari H, Yaghoobbi M, Tavazohi H. Self-assessment of the non-communicable disease surveillance system in Medical University of Isfahan based on the model suggested by the World Health Organization. J Sch Public Health Instit Public Health Res 2010;8(3):47-60. (In Persian) Link
4. Karimi S, Javadi M, Jafarzadeh F. Economic burden and costs of chronic diseases in Iran and the World. Health Inform Manag 2012;8(7):984-96. (In Persian) Link
5. World Health Organization. Preventing chronic diseases: a vital investment: WHO global report. Geneva: World Health Organization; 2005. Link
6. Cost of non-communicable diseases. The European Commission's Science and Knowledge Service. Available at: URL: www.ifpma.org/fileadmin/.../2_PFCD-Cost-of-NCDs_8.5x11.pdf; 2011. Link
7. DeVol R, America AU. The economic burden of chronic disease-charting a new course to save lives and increase productivity and economic growth. New Jersey: Milken Institute; 2007. Link
8. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442. PMID: 17132052 [
DOI:10.1371/journal.pmed.0030442]
9. World Health Organization, World Economic Forum. From burden to "Best Buys": reducing the economic impact of non-communicable diseases in low-and middle-income countries. Geneva: World Health Organization; 2011. Link
10. World Health Organization. The impact of chronic disease in the Islamic Republic of Iran. Geneva: World Health Organization; 2012. Link
11. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007;7(1):32-7. PMID: 17971195 [
DOI:10.1186/1471-2261-7-32]
12. Evans DB, Tandon A, Murray CJ, Lauer JA. Comparative efficiency of national health systems: cross national econometric analysis. BMJ 2001;323(7308):307-10. PMID: 11498486 [
DOI:10.1136/bmj.323.7308.307]
13. Hutubessy RC, Baltussen RM, Torres-Edejer TT, Evans DB. Generalised cost-effectiveness analysis: an aid to decision making in health. Appl Health Econ Health Policy 2002;1(2):89-95. Link
14. Lakić D, Tasić L, Kos M. Economic burden of cardiovascular diseases in Serbia. Vojnosanit Pregl 2014;71(2):137-43. PMID: 24665570 [
DOI:10.2298/VSP1402137L]
15. Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010;15(8):883-93. PMID: 20667966 [
DOI:10.1634/theoncologist.2010-0005]
16. Stommel M, Given CW, Given BA. The cost of cancer home care to families. Cancer 1993;71(5):1867-74. Link
https://doi.org/10.1002/1097-0142(19930301)71:5<1867::AID-CNCR2820710525>3.0.CO;2-7 [
DOI:10.1002/1097-0142(19930301)71:53.0.CO;2-7]
17. Karan A, Engelgau M, Mahal A. The household-level economic burden of heart disease in India. Trop Med Int Health 2014;19(5):581-91. PMID: 24612174 [
DOI:10.1111/tmi.12281]
18. Ebadifard Azar F, Rezapour A. Economic evaluation. 1st ed. Tehran. The Organization for Researching and Composing University Textbooks in the Humanities (SAMT); 2014. Link
19. Weinstein MC, Russell LB, Gold MR, Siegel JE. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996. Link
20. Geravandi S, Pakdaman M. Comment on: estimating economic burden of cancer deaths attributable to smoking in Iran in 2012. J Res Health Sci 2016;16(2):96-7. PMID: 27497778
21. Emamgholipour S, Sari AA, Pakdaman M, Geravandi S. Economic burden of cardiovascular disease in the southwest of Iran. Int Cardiovasc Res J 2018;12(1):1-6. Link
22. Larijani B, Fakhrzadeh H, Mohaghegh M, Pourebrahim R, Akhlaghi MR. Burden of coronary heart disease on the Iranian oil industry (1999-2000). East Mediterr Health J 2003;9(5-6):904-10. PMID: 16450520
23. Raghfar H, Sargazi N, Mehraban S, Akbarzadeh MA, Vaez Mahdavi MR, Vahdati Manesh Z. The economic burden of coronary heart disease in Iran: a bottom-up approach in 2014. J Ardabil Univ Med Sci 2018;18(3):341-56. Link [
DOI:10.29252/jarums.18.3.341]
24. Emamgholipour S, Akbari Sari A, Geravandi S, Mazrae H. Estimation of out-of-pocket and catastrophic expenditures among patients with cardiovascular diseases in Khuzestan. J Payavard Salamat 2017;11(3):297-307. (In Persian) Link
25. Chang HS, Kim HJ, Nam CM, Lim SJ, Jang YH, Kim S, et al. The socioeconomic burden of coronary heart disease in Korea. J Prev Med Public Health 2012;45(5):291-300. PMID: 23091654 [
DOI:10.3961/jpmph.2012.45.5.291]
26. Łyszczarz B. Indirect costs and public finance consequences of heart failure in Poland, 2012-2015. BMC Public Health 2018;18(1):1130. PMID: 30231932 [
DOI:10.1186/s12889-018-6034-0]
27. Walker IF, Garbe F, Wright JM, Newell I, Athiraman N, Khan N, et al. The economic costs of cardiovascular disease, diabetes mellitus, and associated complications in south Asia: a systematic review. Value Health Reg Issues 2018;15:12-26. PMID: 29474174 [
DOI:10.1016/j.vhri.2017.05.003]
28. Kotseva K, Gerlier L, Sidelnikov E, Kutikov L, Lamotte M, Amarenco P, et al. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. Eur J Prev Cardiol 2019;26(11):1150-7. PMID: 30955367 [
DOI:10.1177/2047487319834770]
29. Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, et al. Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden. Eur J Health Econ 2016;25(17):1117-24. PMID: 26607457 [
DOI:10.1007/s10198-015-0749-y]